CN Patent

CN104436194B — 具有协同增效作用的抗癌组合物

Assigned to Peking University · Expires 2018-03-30 · 8y expired

What this patent protects

本发明涉及一种具有协同增效作用的抗癌组合物，具体为包括有效量的至少一种VEGF/VEGFR抑制剂和多巴胺的组合物。本发明的组合物能够明显抑制肿瘤细胞的生长，大大减少抗癌药的使用，降低治疗风险和成本，具有广阔的应用前景。

USPTO Abstract

本发明涉及一种具有协同增效作用的抗癌组合物，具体为包括有效量的至少一种VEGF/VEGFR抑制剂和多巴胺的组合物。本发明的组合物能够明显抑制肿瘤细胞的生长，大大减少抗癌药的使用，降低治疗风险和成本，具有广阔的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN104436194B
Jurisdiction
CN
Classification
—
Expires
2018-03-30
Drug substance claim
No
Drug product claim
No
Assignee
Peking University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.